Avalo Therapeutics CMO Doyle Mittie's Stock Transactions and Option Exercises

Avalo Therapeutics, Inc. (AVTX) Chief Medical Officer Doyle Mittie executed multiple stock transactions on June 30, 2026, pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Mittie exercised two stock options: 2,875 shares at $12.65 per share and 1,779 shares at $8.04 per share, acquiring the underlying common stock while disposing of the options. He then sold 4,654 shares of common stock at $20.00 per share. Following these transactions, Mittie holds 51,776 shares of common stock directly and retains options for 115,092 shares. The options have vesting schedules extending through 2025-2026 with expiration dates in 2034 and 2035. These transactions represent routine executive stock activity under a pre-established trading plan.